Therapeutic Efficacy and Minimum Cost Analysis of Two Chemotherapeutic Regimens for the First Line Treatment of Advance Gastric Cancer / 中国药房
China Pharmacy
;
(12): 3617-3619, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-502657
ABSTRACT
OBJECTIVE:
To evaluate clinical efficacy and the effect of pharmacoeconomics of two chemotherapeutic regimens for the first line treatment of advanced gastric cancer.METHODS:
98 patients with advanced gastric cancer receiving SOX or FLO regimen as first line chemotherapy in our hospital were enrolled. According to chemotherapy grouping,short-term efficacy,toxic re-action and pharmacoeconomics effect were analyzed and compared between 2 groups.RESULTS:
There were a total of 55 patients in SOX group,with effective rate of 38.18%;43 patients in FLO group,with effective rate of 32.56%;there was no statistical sig-nificance in effective rate between 2 groups(P>0.05). There was no statistical significance in toxicities between 2 groups,includ-ing nausea and vomiting,neurotoxicity and neutropenia(P>0.05). The total cost of FLO regimen group was 9 136.98 yuan,while that of SOX regimen group was 12 345.97 yuan. Using minimum cost method,FLO regimen was superior to SOX regimen regard-ing the economical index.CONCLUSIONS:
SOX and FLO regimen have no significant difference for the first-line treatment of ad-vanced gastric cancer in terms of response rate and toxicities. Taking into account the parmocyeconomics,FOL regimen is superior to SOX regimen.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
Language:
Chinese
Journal:
China Pharmacy
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS